FDA notifications. Accelerated approval for raltegravir tablets.
D004311:Double-Blind Method; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D015658:HIV Infections / Q000188:drug therapy*; D019428:HIV Integrase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009930:Organic Chemicals / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D011760:Pyrrolidinones; D000068898:Raltegravir Potassium; D013607:Tablets; D014481:United States; D014486:United States Food and Drug Administration
D019428:HIV Integrase Inhibitors; D009930:Organic Chemicals; D010919:Placebos; D011760:Pyrrolidinones; D013607:Tablets; D000068898:Raltegravir Potassium